LONDON, Nov. 28, 2017 /PRNewswire/ — Do KOLs see a future for beta-amyloid as a target in Alzheimer’s?
Despite the inexorable attrition rate, both big pharma and small biotechs continue to invest in Alzheimer’s disease R&D. Is the amyloid hypothesis dead or could the right drug candidate, studied in an optimally designed trial, gain approval for this much sought after indication? KOLs weigh in on how trials could be optimised and what part biomarkers can play. How can we learn from past failures? What are the chances of success for Biogen/Eisai’s aducanumab and the other beta-amyloid mAbs, as well as the BACE inhibitors, in light of the chequered history of these classes? Could tau finally prove itself as a valid target? Could drugs targeting inflammatory mechanisms or serotonin receptors play a part in this narrative? Four US and seven EU KOLs offer critical insights on four marketed and 15 pipeline drugs.
Download the full report: https://www.reportbuyer.com/product/5214613
Take a tour of the report now
• The table of contents >
• The key business questions answered >
• The key KOL quotes >
• See the therapies covered >
• Find out who the 7 EU & 4 US KOLs are >
• Review an extract from the report – 1 drug profile >
• Clinical attrition in the AD pipeline remains remarkably high. What do KOLs attribute this to and how can these issues be overcome so that past mistakes can be learnt from and the field moved forward?
• Several high profile failures of beta-amyloid mAbs have cast a shadow over this class.How do KOLs account for this chequered history and how do they rate the chance of success for Biogen/Eisai’s aducanumab and other drugs in this class?
• BACE inhibitors in the late-stage pipeline are extremely potent in terms of impacting beta-amyloid, but their clinical value remains uncertain. What is considered the optimal patient population for these drugs, and how do KOLs rate their safety and overall chance of success?
• How do KOLs envisage that the pathophysiological heterogeneity of AD could be exploited for therapeutic gain? Could there be potential in targeting beta-amyloid, tau, inflammatory pathways or serotonergic neurotransmission, or a combination of these?
• Biomarkers have played an increasingly important role in drug development for AD in recent years. How will their use evolve to shape trial design and the treatment of AD in the future?
• Outcome measure selection will be of critical importance to the success of